Author: Ragothaman Srinivasan

[ad_1] Pfizer PFE announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals…

[ad_1] The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s TCON lead asset envafolimab (KN035) for patients with locally advanced, unresectable…

[ad_1] Akero Therapeutics AKRO revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with…

[ad_1] Lyra Therapeutics LYRA advanced into its Part 2 of the Phase 2 BEACON clinical trial of LYR-220 in adults with chronic rhinosinusitis (CRS) who have had a prior sinus…

[ad_1] The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GENFIT’s GNFT drug candidate GNS5611 (ezurpimtrostat) for the treatment of cholangiocarcinoma. The pre-clinical studies evaluating GNS561…